Hypothesis

Senolytics remove senescent cells but may eliminate a beneficial negotiating role they play in tissue homeostasis. Instead of killing these cells, pharmacologically disrupting the BCL‑2/Beclin‑1 interaction to revive autophagy will shift the senescence‑associated secretory phenotype (SASP) toward anti‑inflammatory mediators, allowing senescent cells to continue signaling immune tolerance while limiting pathological inflammation.

Mechanistic Basis

In senescent cells, BCL‑2 binds Beclin‑1 at the ER, suppressing autophagy and driving a SASP rich in IL‑1α, IL‑8 and other NF‑κB‑dependent cytokines that propagate paracrine senescence and inflammation 1. Autophagy failure amplifies this inflammatory SASP, whereas restored autophagy promotes degradation of inflammasome components and favors secretion of TGF‑β and IL‑10, cytokines known to recruit regulatory T cells (Tregs) and support tissue repair 2. The Beclin‑1 F121A mutation, which weakens BCL‑2/Beclin‑1 binding, rescues premature aging phenotypes by increasing autophagic flux, suggesting that the complex’s activity directly determines SASP quality 3.

Predictions

1. Treatment with a selective BH3 mimetic that disrupts BCL‑2/Beclin‑1 (e.g., a non‑apoptotic BH3 peptide) will increase LC3‑II/I ratios and p62 degradation in senescent fibroblasts and epithelial cells without activating caspase‑3.
2. This autophagy restoration will decrease secretion of IL‑1α, IL‑6 and IL‑8 while increasing TGF‑β and IL‑10 in the conditioned medium.
3. In vivo, aged mice receiving the BH3 mimetic will show elevated autophagic flux in p16^high^ cells, increased Treg infiltration into tissues such as lung and liver, and reduced collagen deposition compared with vehicle controls, despite unchanged numbers of p16^high^ cells.
4. If autophagy is genetically blocked (e.g., Atg5 knockout) in senescent cells, the BH3 mimetic will fail to shift the SASP toward immunosuppressive cytokines, confirming the autophagy‑dependent mechanism.

Experimental Approach

• In vitro: Isolate primary human fibroblasts, induce senescence via irradiation, treat with BH3 mimetic or control. Measure autophagic flux (mCherry‑GFP‑LC3 assay), cytokine profiling (Luminex), and apoptosis (Annexin V/PI).
• In vivo: Use naturally aged C57BL/6 mice (24 months). Administer BH3 mimetic or saline twice weekly for 4 weeks. Assess senescence (p16^Ink4a^‑GFP reporter), autophagy (LC3 puncta in sorted p16^+^ cells), cytokine levels in tissue homogenates, Treg frequency (FoxP3^+^ CD4^+^), and histology for fibrosis (Masson’s trichrome).
• Genetic validation: Cross p16‑3MR mice with Atg5^fl/fl^; administer BH3 mimetic and tamoxifen to delete Atg5 specifically in senescent cells, then repeat SASP and Treg analyses.

Potential Outcomes

If the hypothesis holds, BH3 mimetic treatment will convert senescent cells from inflammatory broadcasters to immunomodulatory negotiators, expanding the therapeutic window beyond senolysis. Failure to observe the predicted SASP shift or an increase in tissue damage would falsify the idea that autophagy restoration in senescent cells preserves a beneficial negotiating function.